COLLEGIUM PHARMACEUTICAL, INC (COLL) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$23.20

From 52W high−53.83%

Volume713866.00

Market cap$713.29M

P/E (TTM)15.0x

P/S (TTM)0.9x

Div yield—

Key dataOct 19, 2026

Open

$23.20

From 52W high

−53.83%

Volume

713866.00

Market cap

$713.29M

ValuationView details →

P/E (Fwd)

3.3x

EV/EBITDA

3.0x

P/E (TTM)

15.0x

RSI (14)

55.0

MomentumView details →

1D Return

−0.78%

YTD Return

−49.34%

SummaryUpdated Jun 1, 2026

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a specialty pharmaceutical company founded in 2002 and headquartered in Stoughton, Massachusetts. The company went public in May 2015 and has evolved from a development-stage company into a commercial-stage pharmaceutical business focused on pain management and neuropsychiatric disorders. Through strategic acquisitions, including the 2018 purchase of BioDelivery Sciences International and the 2024 acquisition of Ironshore Therapeutics, Collegium has built a diversified portfolio of branded prescription medications that address significant unmet medical needs in pain management and ADHD treatment.

Ask drillr about COLLEGIUM PHARMACEUTICAL, INC →

ValuationView details →

P/E (Fwd)

3.3x

P/E (TTM)

15.0x

EV/EBITDA

3.0x

EV/Sales

1.8x

P/S (TTM)

0.9x

P/B (TTM)

2.3x

ProfitabilityView details →

Gross Margin

60.02%

Net Margin

5.93%

EBITDA Margin

58.57%

ROE (TTM)

15.36%

ROA (TTM)

2.24%

Asset Turnover

0.43x

GrowthView details →

Revenue YoY

+14.31%

EPS YoY

+30.10%

FCF YoY

+62.67%

Revenue CAGR 3Y

+18.94%

EPS CAGR 3Y

+11.24%

EBITDA YoY

+36.53%

MomentumView details →

1D Return

−0.78%

YTD Return

−49.34%

1Y Return

−32.70%

RSI (14)

55.0

vs 50D SMA

−2.57%

vs 200D SMA

−31.61%

Capital & dividendView details →

Debt/Equity

2.75x

Current Ratio

1.03x

Quick Ratio

0.84x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$1.92

EPS Surprise

11.63%

Beats (12Q)

8/12

Next Q EPS Est

$1.98

Avg Surprise (4Q)

−8.35%

Rev Surprise

0.13%

Financials snapshotView financials →

Revenue (TTM)

808.21M

Net Income (TTM)

47.91M

Op. CF (TTM)

329.92M

Next earningsNov 5, 2026 →

Latest newsMore news →

Collegium Pharmaceutical launched "Start Talking ADHD," an online resource hub offering practical guides for people living with ADHD and their families.14d ago

Collegium Pharmaceutical entered into an accelerated share repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, part of a $150 million buyback program authorized in July 2025.68d ago

Similar companies

Pak Fah Yeow International Limited00239.HK Fusen Pharmaceutical Company Limited01652.HK Lee's Pharmaceutical Holdings Limited00950.HK Esperion Therapeutics, Inc.ESPR Ironwood Pharmaceuticals, Inc.IRWD Zhongzhi Pharmaceutical Holdings Limited03737.HK Find similar companies →

Latest newsMore news →

Collegium Pharmaceutical launched "Start Talking ADHD," an online resource hub offering practical guides for people living with ADHD and their families.14d ago Collegium Pharmaceutical entered into an accelerated share repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, part of a $150 million buyback program authorized in July 2025.68d ago